This weekend is a big weekend for many biotech investors, as two big conferences get started on Saturday. Here's a breakdown of the big names involved and a preview of what investors can expect.
American Academy of Neurology Conference: April 18-25, Washington, D.C.
Biogen Inc BIIBInvestors will be watching Biogen for more data on its potential Alzheimer's drug BIIB037, although the critical data isn't expected until later in 2015. Investors are anxious to see if the drug will eventually penetrate the $20 billion-plus Alzheimer's market.
PTC Therapeutics, Inc. PTCT
PTC is expected to present data on its drug RG7800, a potential treatment for muscular atrophy. PTC and partner Rocke are hoping that the drug, which is taken orally, can provide a better treatment alternative than Isis Pharmaceuticals, Inc. ISIS and Biogen's potential treatment, which is injected into patients' spinal fluid.
Alnylam Pharmaceuticals, Inc. ALNY
Alnylam and Isis are both developing potential treatments for TTR amyloidosis, and updates on these medicines will likely be included in the companies' presentations.
American Association For Cancer Research Conference: April 18-22, Philadelphia, Pennsylvania
Merck & Co, Inc.MRKMerck and Bristol-Myers are headlining this year's conference, and analysts are looking for data on key cancer drugs from both companies ahead of next month's American Society of Clinical Oncology meeting.
CAR-T Names
Analysts are waiting on data from chimeric antigen T-cell receptor immunotherapy studies that could come at the conference.
Any data on this front could have a huge impact on Novartis AG (ADR) NVS, Juno Therapeutics Inc JUNO, Bellicum Pharmaceuticals Inc BLCM, Kite Pharma Inc KITE and ZIOPHARM Oncology Inc. ZIOP.
Other Companies
Analysts will also be looking for any new data on treatments from Incyte Corporation INCY, Infinity Pharmaceuticals Inc. INFI and Pharmacyclics, Inc. PCYC.
Positive news from any of these companies could make big waves in the stock market.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.